Compile Data Set for Download or QSAR
Report error Found 209 Enz. Inhib. hit(s) with all data for entry = 13025
TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752614(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3-(difluorom...)
Affinity DataIC50: 2.82nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752624(3-tert-butyl-1,8-dimethyl-5-[[(1R)- 1-[3-(2-amino-...)
Affinity DataIC50: 5.01nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752692(1-cyclopropyl-3-methoxy-3,5- dimethyl-8-[[(1R)-1-[...)
Affinity DataIC50: 5.75nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752646(1,8-dimethyl-3-(1- methylcyclopropyl)-5-[[(1R)-1-[...)
Affinity DataIC50: 6.03nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752625(1,3,8-trimethyl-5-[[(1R)-1-[2- methyl-3- (trifluor...)
Affinity DataIC50: 6.17nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752704(3-ethoxy-1,3,5-trimethyl-8-[[(1R)- 1-[3-(1, 1-difl...)
Affinity DataIC50: 6.17nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752650(3-tert-butyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-difl...)
Affinity DataIC50: 6.17nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752694(1-isopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-di...)
Affinity DataIC50: 6.17nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752698(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.31nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752691(1-cyclopropyl-5-methyl-8-[[(1R)- 1-[3-(1,1-difluor...)
Affinity DataIC50: 6.31nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752686(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752685(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752699(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752695(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752629(3-cyclopropyl-1,8-dimethyl-5- [[1R)-1-[2-methyl-3-...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752708(1-cyclopropyl-8-[[(1R)-1-[3-(1,1- difluoro-2-hydro...)
Affinity DataIC50: 6.61nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752649(1-isopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-di...)
Affinity DataIC50: 6.76nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752759(1',5'-dimethyl-8'-[[(1R)-1-[3-(1,1- difluoro-2-hyd...)
Affinity DataIC50: 6.76nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752643(1,5-dimethyl-8-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 6.92nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752680(1-isopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-di...)
Affinity DataIC50: 7.08nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752679(1,3,3,5-tetramethyl-8-[[(1R)-1-[3- (1,1-difluoro-2...)
Affinity DataIC50: 7.08nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752700(3-ethoxy-1,3,5-trimethyl-8-[[(1R)- 1-[3-(1,1-diflu...)
Affinity DataIC50: 7.24nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752689(1-cyclopropyl-5-methyl-8-[[(1R)- 1-[3-(1,1-difluor...)
Affinity DataIC50: 7.41nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752638(3-cyclopropyl-1,8-dimethyl-5- [[(1R)-1-[3-(1,1-dif...)
Affinity DataIC50: 7.41nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752665(1,3,3,8-tetramethyl-5-[[(1R)-1-[3- (1,1-difluoro-2...)
Affinity DataIC50: 7.41nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752681(1-isopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-di...)
Affinity DataIC50: 7.41nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752663(3-methoxy-1,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-difl...)
Affinity DataIC50: 7.41nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752609(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[2-fluoro-3- ...)
Affinity DataIC50: 7.59nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752587(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-diflu...)
Affinity DataIC50: 7.59nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752658(1,5-dimethyl-8-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 7.76nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752673(3-tert-butyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-difl...)
Affinity DataIC50: 7.94nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752702(3-ethoxy-1,3,5-trimethyl-8-[[(1R)- 1-[3-(1, 1-difl...)
Affinity DataIC50: 7.94nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752653(1,8-dimethyl-3-(1- methylcyclopropyl)-5-[[(1R)-1-[...)
Affinity DataIC50: 7.94nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752701(1,8-dimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 7.94nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752630(1-cyclopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-...)
Affinity DataIC50: 7.94nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752623(3-cyclopropyl-1,8-dimethyl-5- [[(1R)-1-[2-fluoro-3...)
Affinity DataIC50: 8.13nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752669(1,3,3,8-tetramethyl-5-[[(1R)-1-[3- (1,1-difluoro-2...)
Affinity DataIC50: 8.13nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752635(1,3,8-trimethyl-5-[[(1R)-1-[3-(1,1- difluoro-2-hyd...)
Affinity DataIC50: 8.13nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752585(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3- (trifluor...)
Affinity DataIC50: 8.13nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752659(1,5-dimethyl-8-[[(1R)-1-[3-(1,1- difluoro-2-hydrox...)
Affinity DataIC50: 8.13nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752672(3-methoxy-1,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-difl...)
Affinity DataIC50: 8.32nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752655(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-diflu...)
Affinity DataIC50: 8.32nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752588(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-diflu...)
Affinity DataIC50: 8.32nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752756(1',5'-dimethyl-8'-[[(1R)-1-[3-(1,1- difluoro-2-hyd...)
Affinity DataIC50: 8.32nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752657(3-isopropyl-1,8-dimethyl-5-[[(1R)- 1-[3-(1,1-diflu...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752703(3-ethoxy-1,3,5-trimethyl-8-[[(1R)- 1-[3-(1, 1-difl...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752637(1-cyclopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752764(1',5'-dimethyl-8'-[[(1R)-1-[3-(1,1- difluoro-2-hyd...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752651(1-isopropyl-3,3,5-trimethyl-8- [[(1R)-1-[3-(1,1-di...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM752777(3-ethyl-3-methoxy-1,5-dimethyl- 8-[[(1R)-1-[3-(1,1...)
Affinity DataIC50: 8.51nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
US Patent

Displayed 1 to 50 (of 209 total ) | Next | Last >>
Jump to: